Valuation : MiMedx Group, Inc.

Market Cap 656M 565M 530M 484M 911M 62.69B 914M 6.29B 2.45B 31.65B 2.46B 2.41B 105B P/E 2026 *
-26.5x
P/E 2027 * 61.4x
Enterprise Value 656M 565M 530M 484M 911M 62.69B 914M 6.29B 2.45B 31.65B 2.46B 2.41B 105B EV / Sales 2026 *
2.43x
EV / Sales 2027 * 2x
Free-Float
95.58%
Yield 2026 *
-
Yield 2027 * -
1 day-0.78%
1 week+4.10%
Current month+7.63%
1 month+7.63%
3 months+24.16%
6 months-6.62%
Current year-34.34%
1 week 4.27
Extreme 4.27
4.76
1 month 4.05
Extreme 4.05
4.76
Current year 3.02
Extreme 3.025
6.79
1 year 3.02
Extreme 3.025
7.97
3 years 3.02
Extreme 3.025
10.14
5 years 2.43
Extreme 2.43
15.99
10 years 0.95
Extreme 0.95
18.25
Manager TitleAgeSince
Chief Executive Officer 62 2023-01-26
Director of Finance/CFO 60 2023-07-04
Chief Tech/Sci/R&D Officer - 2021-05-31
Director TitleAgeSince
Director/Board Member 73 2019-06-18
Chairman 73 2019-06-18
Director/Board Member 63 2019-06-18
Date Insider Type Main position Quantity % Market Cap. Importance
7/2/26 Tax

Chief Financial Officer

-12,749 0.0086%
3/13/26 Tax

Executive/Senior Manager

6,762 0.0046%
3/13/26 Tax

Chief Administrative Officer

20,245 0.0136%
Change 5-day change 1-year change 3-year change Capi.($)
-0.78%+4.10%-38.18%-40.09% 656M
-3.02%+0.18%+85.84% - 355M
+1.23%-5.99%-33.94%-7.81% 128M
-5.31%-2.00%-24.90%+29.80% 81.14M
Average -1.97%+4.59%-2.79%-6.04% 304.89M
Weighted average by Cap. -1.52%+3.00%-0.78%-28.77%

Financials

2026 *2027 *
Net sales 270M 233M 218M 199M 375M 25.79B 376M 2.59B 1.01B 13.02B 1.01B 991M 43.16B 329M 283M 265M 242M 457M 31.4B 458M 3.15B 1.23B 15.85B 1.23B 1.21B 52.56B
Net income -25.45M -21.93M -20.56M -18.77M -35.36M -2.43B -35.47M -244M -95.18M -1.23B -95.55M -93.47M -4.07B 11.23M 9.68M 9.08M 8.28M 15.61M 1.07B 15.66M 108M 42.01M 542M 42.18M 41.26M 1.8B
Net Debt - -
Logo MiMedx Group, Inc.
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Employees
808
Date Price Change Volume
26-08-31 US$4.445 -1.22% 163,551
26-08-28 US$4.500 -0.22% 887,017
26-08-27 US$4.510 +2.04% 1,179,464
26-08-26 US$4.420 +1.84% 711,026
26-08-25 US$4.340 +1.64% 700,021
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.500USD
Average target price
7.400USD
Spread / Average Target
+64.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDXG Stock